Clinical Trials
27 trialsAML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia
First Affiliated Hospital Xi'an Jiaotong University
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
University of Chicago
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Northwestern University
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
University of Southern California
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
VIAC
University of Alberta
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
University Health Network, Toronto
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
Rutgers, The State University of New Jersey
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
University of Rochester
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
The Cleveland Clinic
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Roswell Park Cancer Institute
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
Case Comprehensive Cancer Center
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
Case Comprehensive Cancer Center
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells
University of Bologna